These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 1386282)

  • 21. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
    Suminaga M; Furue H; Taguchi T; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1879-90. PubMed ID: 1387774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
    Jeremić B
    Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
    Lajolo PP; de Camargo B; del Giglio A
    Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
    Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
    Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
    Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
    J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trials of ondansetron with high-dose cisplatin.
    Kris MG
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):23-7. PubMed ID: 1387247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
    Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
    Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis.
    Roila F; Bracarda S; Tonato M; Marangolo M; Bella M; Donati D; Cetto G; Del Favero A
    Clin Oncol (R Coll Radiol); 1990 Sep; 2(5):268-72. PubMed ID: 2148109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
    Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
    Ossi M; Anderson E; Freeman A
    Oncology; 1996 Jun; 53 Suppl 1():78-85. PubMed ID: 8692556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.